Oncosec Medical (ONCS) – Press Releases
-
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
-
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
-
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
-
OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022
-
OncoSec Announces Pricing of $3.5 Million Public Offering
-
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
-
OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
-
OncoSec Announces Reverse Stock Split
-
OncoSec Announces Pipeline Prioritization and Workforce Reduction
-
Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research
-
OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research
-
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
-
OncoSec Announces Appointment of George Chi as Chief Financial Officer
-
OncoSec Announces Changes to its Board of Directors
-
OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study
-
OncoSec Provides Business Update
-
OncoSec Provides Leadership Update
-
OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
-
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
-
OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer
-
OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering
-
OncoSec to Present at the Raymond James Human Health Innovation Conference
-
OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management
-
OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma
-
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors
-
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
-
OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer
-
OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits
-
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
-
OncoSec Strengthens Management Team With Two New Appointments
-
OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein
-
OncoSec Medical Closes $42.0 Million Public Offering of Common Stock
-
OncoSec Medical Announces Pricing of $42.0 Million Public Offering of Common Stock
-
OncoSec Medical Announces Proposed Public Offering of Common Stock
-
Sirtex Medical announces collaboration update with OncoSec Medical
-
OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™
-
OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma
-
OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO™ and Its Gene Electrotransfer Technology
-
OncoSec Announces Publication in International Journal of Surgery Case Reports
-
OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics
-
OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment
-
OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020
-
OncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
-
OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020
-
OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19
-
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Back to ONCS Stock Lookup
